THE EFFECT OF ORAL ONDANSETRON IN THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING AFTER MAJOR GYNECOLOGICAL SURGERY PERFORMED UNDER GENERAL-ANESTHESIA

被引:44
作者
DUPEYRON, JP
CONSEILLER, C
LEVARLET, M
HEMMINGSEN, C
SCHOEFFLER, P
PEDERSEN, FM
GRIBOMONT, B
KAPLAN, LA
机构
[1] MATERNITE PORT ROYAL,PARIS,FRANCE
[2] HOP ERASME,BRUSSELS,BELGIUM
[3] UNIV HOSP COPENHAGEN,HERLEV,DENMARK
[4] RIGSHOSP,DK-2100 COPENHAGEN,DENMARK
[5] CHU CLERMONT FERRAND,F-63003 CLERMONT FERRAND,FRANCE
[6] CLIN UNIV ST LUC,B-1200 BRUSSELS,BELGIUM
[7] GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND
关键词
VOMITING; NAUSEA; ANTIEMETICS; PHARMACOLOGY; ONDANSETRON;
D O I
10.1111/j.1365-2044.1993.tb06904.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
The efficacy and safety of ondansetron in preventing postoperative nausea and vomiting following major gynaecological surgery was evaluated in this multicentre, double‐blind study. A total of 243 patients were randomised to receive three doses of oral ondansetron 8 mg or matching placebo at 8‐hourly intervals, with the first dose being given an hour before surgery. A standard general anaesthetic technique was employed throughout. Nausea, vomiting and safety assessments were performed continuously during the 24 h postrecovery period. Of the 237 patients evaluated for efficacy, significantly fewer ondansetron 8 mg treated patients (65/117: 56%) experienced postoperative nausea and/or vomiting compared with placebo‐treated patients (94/120; 78%) during the study period (p < 0.001). In addition, ondansetron 8 mg reduced the severity of nausea (p < 0.001) and the total number of vomiting episodes experienced (p < 0.001). Overall, ondansetron 8 mg was well tolerated and effective in preventing postoperative nausea and vomiting in this surgical setting. Copyright © 1993, Wiley Blackwell. All rights reserved
引用
收藏
页码:214 / 218
页数:5
相关论文
共 15 条
[1]  
BODNER M, 1991, ANESTH ANALG, V73, P250
[2]   THE EFFECT OF GR38032F, NOVEL 5-HT3-RECEPTOR ANTAGONIST ON GASTRIC-EMPTYING IN THE GUINEA-PIG [J].
COSTALL, B ;
GUNNING, SJ ;
NAYLOR, RJ ;
TYERS, MB .
BRITISH JOURNAL OF PHARMACOLOGY, 1987, 91 (02) :263-264
[3]   PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST [J].
CUNNINGHAM, D ;
POPLE, A ;
FORD, HT ;
HAWTHORN, J ;
GAZET, JC ;
CHALLONER, T ;
COOMBES, RC .
LANCET, 1987, 1 (8548) :1461-1463
[4]   THE EFFICACY OF GR38032F, AN ANTAGONIST OF 5-HYDROXYTRYPTAMINE-3 (5-HT3) IN THE PROPHYLAXIS OF CISPLATIN (CDDP)-INDUCED NAUSEA AND VOMITING [J].
DEHAAN, LD ;
DEMULDER, PHM ;
BEEX, LVAM ;
DEBRUYNE, FMJ ;
CHALLONER, T ;
DEPAUW, BE .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (08) :1383-1384
[5]  
GUNNING S J, 1987, British Journal of Pharmacology, V90, p135P
[6]  
LARIJANI GE, 1991, ANESTH ANALG, V73, P246
[7]  
LEESER J, 1991, ANESTH ANALG, V72, P751
[8]   COMPARISON OF THE USE OF DOMPERIDONE, DROPERIDOL AND METOCLOPRAMIDE IN THE PREVENTION OF NAUSEA AND VOMITING FOLLOWING MAJOR GYNECOLOGICAL SURGERY [J].
MADEJ, TH ;
SIMPSON, KH .
BRITISH JOURNAL OF ANAESTHESIA, 1986, 58 (08) :884-887
[9]  
MCKENZIE R, 1990, ANESTHESIOLOGY, V73, pA739
[10]   ANESTHESIA AND EMESIS .1. ETIOLOGY [J].
PALAZZO, MGA ;
STRUNIN, L .
CANADIAN ANAESTHETISTS SOCIETY JOURNAL, 1984, 31 (02) :178-187